DE502004009690D1 - 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose - Google Patents

4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Info

Publication number
DE502004009690D1
DE502004009690D1 DE502004009690T DE502004009690T DE502004009690D1 DE 502004009690 D1 DE502004009690 D1 DE 502004009690D1 DE 502004009690 T DE502004009690 T DE 502004009690T DE 502004009690 T DE502004009690 T DE 502004009690T DE 502004009690 D1 DE502004009690 D1 DE 502004009690D1
Authority
DE
Germany
Prior art keywords
ylmethoxy
cyclohexyloxy
oxazole
atherosclerosis
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE502004009690T
Other languages
English (en)
Inventor
Christian Stapper
Stefanie Keil
Heiner Glombik
Eugen Falk
Jochen Goerlitzer
Dirk Gretzke
Hans-Ludwig Schaefer
Wolfgang Wendler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of DE502004009690D1 publication Critical patent/DE502004009690D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
DE502004009690T 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose Expired - Lifetime DE502004009690D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
DE502004009690D1 true DE502004009690D1 (de) 2009-08-13

Family

ID=32920629

Family Applications (4)

Application Number Title Priority Date Filing Date
DE10308355A Withdrawn DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE502004009453T Expired - Lifetime DE502004009453D1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE502004009690T Expired - Lifetime DE502004009690D1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE502004004139T Expired - Lifetime DE502004004139D1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE10308355A Withdrawn DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE502004009453T Expired - Lifetime DE502004009453D1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502004004139T Expired - Lifetime DE502004004139D1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Country Status (34)

Country Link
US (5) US7259177B2 (de)
EP (3) EP1599455B1 (de)
JP (3) JP2006519199A (de)
KR (3) KR20050105492A (de)
CN (3) CN100439347C (de)
AR (3) AR043433A1 (de)
AT (3) ATE435217T1 (de)
AU (3) AU2004215672B2 (de)
BR (3) BRPI0407758A (de)
CA (3) CA2517386A1 (de)
CL (2) CL2004000391A1 (de)
CO (2) CO5690580A2 (de)
DE (4) DE10308355A1 (de)
DK (3) DK1599453T3 (de)
EC (2) ECSP055986A (de)
ES (3) ES2287700T3 (de)
HR (3) HRP20050743A2 (de)
IL (2) IL170314A (de)
MA (3) MA27737A1 (de)
MX (3) MXPA05008988A (de)
NO (3) NO20054408L (de)
OA (2) OA13035A (de)
PA (1) PA8596801A1 (de)
PE (3) PE20050292A1 (de)
PL (3) PL378130A1 (de)
PT (3) PT1599452E (de)
RS (1) RS20050594A (de)
RU (3) RU2005129995A (de)
SA (1) SA04250153A (de)
TN (2) TNSN05204A1 (de)
TW (3) TW200500349A (de)
UY (2) UY28210A1 (de)
WO (3) WO2004076426A1 (de)
ZA (2) ZA200505765B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
BRPI0617207A2 (pt) 2005-09-29 2011-07-19 Sanofi Aventis derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
BRPI0621960A2 (pt) 2006-08-10 2011-12-27 Wood One Co Ltd composiÇço hipoglicÊmica contendo derivado da casca de acÁcia
US8481778B2 (en) 2007-08-16 2013-07-09 Solvay (Societe Anonyme) Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
ES2574159T3 (es) 2008-02-29 2016-06-15 Nissan Chemical Industries, Ltd. Proceso para la producción de compuesto de tiofeno e intermedio del mismo
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
SG11202005446QA (en) 2017-12-13 2020-07-29 Canon Kk Cartridge and image forming apparatus
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
KR19990077319A (ko) 1996-01-17 1999-10-25 한센 핀 베네드, 안네 제헤르 축합된 1,2,4-티아디아진 및 축합된 1,4-티아진 유도체, 그것의제조방법 및 사용
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (de) 1997-07-16 2000-05-17 Novo Nordisk A/S Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
AU5443499A (en) * 1998-08-27 2000-03-21 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (de) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituierte imidazole, ihre herstellung und ihre verwendung
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
CN1183113C (zh) * 1999-04-28 2005-01-05 阿文蒂斯药物德国有限公司 作为ppar受体配体的三芳基酸衍生物
EP1175421A1 (de) 1999-04-30 2002-01-30 Neurogen Corporation 9h-pyrimido[4,5-b]indolderivate: crf1 spezifische liganden
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
EP1194146B1 (de) 1999-06-18 2006-07-19 Merck & Co., Inc. Arylthiazolidinedione und aryloxa zolidinedion-derivate
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
ES2203498T3 (es) 1999-07-29 2004-04-16 Eli Lilly And Company Benzofurilpiperazinas: agonistas de receptor 5-ht2c de la serotonina.
IL148148A0 (en) 1999-09-01 2002-09-12 Aventis Pharma Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
EP1237855B1 (de) 1999-12-03 2004-03-10 AstraZeneca AB Kristalline form von (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenyl-ethoxy)phenyl]propansäure
ES2320630T5 (es) 2000-03-31 2013-03-12 Royalty Pharma Collection Trust Método para la mejora de la señalización de los islotes en diabetes mellitus y para su prevención
CZ20023502A3 (cs) 2000-04-25 2003-06-18 Kyorin Pharmaceutical Co., Ltd. Nová stabilní krystalická forma thiazolidionového derivátu a způsob jeho přípravy
AU2001252574B2 (en) 2000-04-28 2005-03-17 Asahi Kasei Pharma Corporation Novel bicyclic compounds
EP1280777B1 (de) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
HUP0301749A2 (hu) 2000-06-09 2003-09-29 Aventis Pharma Deutschland Gmbh. Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (de) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Verfahren zum Identifizieren von Verbindungen, die die Ubiquitin vermittelte Proteolyse von IkB inhibieren
AU2001284658A1 (en) 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
ES2286137T3 (es) * 2000-08-23 2007-12-01 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
WO2002050027A1 (de) 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
CZ20031772A3 (cs) * 2000-12-25 2003-11-12 Ono Pharmaceutical Co., Ltd. Derivát dihydronaftalenu a činidlo obsahující tento derivát jako účinnou složku
MXPA03007284A (es) 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
HUP0400268A2 (hu) * 2001-06-07 2004-07-28 Eli Lilly And Co. Peroxiszóma proliferátorral aktivált receptorokat (PPAR) módosító hatóanyagok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
AU2002333456B2 (en) 2001-08-31 2008-07-17 Sanofi-Aventis Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
WO2004076426A1 (de) 2004-09-10
RU2005129992A (ru) 2006-02-10
RU2005130002A (ru) 2006-01-27
CN1753881A (zh) 2006-03-29
AR043427A1 (es) 2005-07-27
TNSN05204A1 (en) 2007-06-11
KR20050105492A (ko) 2005-11-04
US7335671B2 (en) 2008-02-26
CN1753879A (zh) 2006-03-29
PT1599452E (pt) 2007-09-12
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
JP2006519199A (ja) 2006-08-24
JP2006519194A (ja) 2006-08-24
CL2004000392A1 (es) 2005-04-22
WO2004076428A1 (de) 2004-09-10
PT1599453E (pt) 2009-07-14
EP1599453B1 (de) 2009-05-06
PE20040959A1 (es) 2005-01-17
US20050215596A1 (en) 2005-09-29
CN1756748A (zh) 2006-04-05
DK1599452T3 (da) 2007-10-01
WO2004076427A1 (de) 2004-09-10
PL377735A1 (pl) 2006-02-20
KR20050106462A (ko) 2005-11-09
NO20054398D0 (no) 2005-09-22
AU2004215672B2 (en) 2010-01-07
US7259177B2 (en) 2007-08-21
EP1599453A1 (de) 2005-11-30
AR043433A1 (es) 2005-07-27
EP1599452A1 (de) 2005-11-30
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
HRP20050742A2 (en) 2006-09-30
CN100439345C (zh) 2008-12-03
ZA200505768B (en) 2005-11-23
SA04250153A (ar) 2005-12-03
IL170314A (en) 2010-11-30
UY28210A1 (es) 2004-09-30
KR20050106461A (ko) 2005-11-09
PL378130A1 (pl) 2006-03-06
DK1599453T3 (da) 2009-08-24
US7365084B2 (en) 2008-04-29
MXPA05008988A (es) 2005-10-18
MXPA05008995A (es) 2005-10-18
DE10308355A1 (de) 2004-12-23
ATE365159T1 (de) 2007-07-15
PT1599455E (pt) 2009-09-29
US20050101637A1 (en) 2005-05-12
OA13034A (en) 2006-11-10
PL378437A1 (pl) 2006-04-03
JP2006519193A (ja) 2006-08-24
CN100439347C (zh) 2008-12-03
MA27737A1 (fr) 2006-02-01
US7872034B2 (en) 2011-01-18
CA2517386A1 (en) 2004-09-10
PE20050293A1 (es) 2005-05-24
AU2004215673A1 (en) 2004-09-10
UY28209A1 (es) 2004-09-30
TW200510352A (en) 2005-03-16
AU2004215673B2 (en) 2009-10-01
BRPI0407758A (pt) 2006-02-14
ATE430738T1 (de) 2009-05-15
ES2287700T3 (es) 2007-12-16
MA27736A1 (fr) 2006-02-01
AR043432A1 (es) 2005-07-27
CN100398526C (zh) 2008-07-02
BRPI0407907A (pt) 2006-02-14
CO5690578A2 (es) 2006-10-31
DK1599455T3 (da) 2009-11-09
CA2517381A1 (en) 2004-09-10
AU2004215677A1 (en) 2004-09-10
EP1599455B1 (de) 2009-07-01
DE502004004139D1 (de) 2007-08-02
RU2005129995A (ru) 2006-01-27
TNSN05206A1 (en) 2007-06-11
HRP20050744A2 (en) 2006-09-30
ES2326418T3 (es) 2009-10-09
NO20054396L (no) 2005-11-11
RS20050594A (en) 2007-12-31
TW200508210A (en) 2005-03-01
AU2004215677B2 (en) 2010-01-07
CA2516620A1 (en) 2004-09-10
EP1599455A1 (de) 2005-11-30
DE502004009453D1 (de) 2009-06-18
ES2329366T3 (es) 2009-11-25
ZA200505765B (en) 2006-05-31
US20080167354A1 (en) 2008-07-10
CL2004000391A1 (es) 2005-01-07
PE20050292A1 (es) 2005-05-24
MA27742A1 (fr) 2006-02-01
AU2004215672A1 (en) 2004-09-10
ATE435217T1 (de) 2009-07-15
OA13035A (en) 2006-11-10
CO5690580A2 (es) 2006-10-31
NO20054398L (no) 2005-11-02
NO20054396D0 (no) 2005-09-22
ECSP055985A (es) 2006-01-16
MXPA05008951A (es) 2005-11-04
US20040209920A1 (en) 2004-10-21
BRPI0407814A (pt) 2006-02-14
US20080015238A1 (en) 2008-01-17
EP1599452B1 (de) 2007-06-20
ECSP055986A (es) 2006-01-16
TW200500349A (en) 2005-01-01
NO20054408D0 (no) 2005-09-22

Similar Documents

Publication Publication Date Title
ATE435217T1 (de) 4-(3- (2-phenyl-oxazol-4-ylmethoxy)- cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
ATE327753T1 (de) Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
DE602004007693D1 (de) (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
EP1756040A4 (de) Als -sekretaseinhibitoren zur behandlung von alzheimer-krankheit geeignete phenylcarbonsäureamidverbindungen
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
WO2006127503A3 (en) Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
EP1740559A4 (de) Als ?-sekretase-inhibitoren für die behandlung von alzheimer-krankheit geeignete 1,3,5-substituierte phenylderivatverbindungen
DE60333371D1 (de) 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen
EP1807396A4 (de) 2-aminopyridinzusammensetzungen als beta-sekretase-hemmer zur behandlung von morbus alzheimer
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
DE502005002310D1 (de) Diphenylaminsubstituierte salicylthiazolderivate und verwandte verbindungen als phosphotyrosinphosphatase 1b (ptp1b) hemmer zur verwendung als blutzuckersenkende wirkstoffe zur behandlung von diabetes
DE602004002394D1 (de) (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
DE602006002608D1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
ATE345340T1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
ATE400273T1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)- ethylcyclohexanol-derivate als monoamin- wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
ATE348611T1 (de) Derivate des phenoxy-n-'4-(isothiazolidin-1,1- dioxid-2yl)pheny)-valerian-säureamids und andere verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen und tumoren
DE602004001492D1 (de) (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-essigsäure Derivate und verwandte tricyclische Indanyle als alphaVbeta3 und alphaVbeta5 Integrin Inhibitoren zur Behandlung von Krebs und instabiler Angina
ATE343571T1 (de) 4-ä'3-(sulfonylamino)phenyl)'1- (cyclymethyl)piperidin-4- ylidene)methylübenzamidederivate als delta-opioid-rezeptorliganden zur behandlung von schmerzen, angstzuständen und funktionellen gastrointestinalen erkrankungen
DE502005007249D1 (de) 2-ä-3-'2-(PHENYL)-OXAZOL-4-YLMETHOXY!-CYCLOHEXYLMETHOXYü-PROPIONSÄURE DERIVATE ALS PPAR-LIGANDEN (PEROXISOMEN-PROLIFERATOREN-AKTIVIERTE REZEPTOREN) ZUR BEHANDLUNG VON HYPERLIPIDÄMIE UND DIABETES

Legal Events

Date Code Title Description
8364 No opposition during term of opposition